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Treatment outcomes of patients on antiretrovirals after six months 
of treatment, Khami Clinic, Bulawayo, Zimbabwe
*RT NCUBE, **Z HW^LIMA, *M TSHIMANGA,*** J CHIRENDA, *B MABAERA, *T APOLLO 
A bstract
Objective: To describe treatm ent outcom es o f  patients on anti-retrovirals at six m onths o f  treatm ent.
Study Design: We conducted pre-intervention post intervention surveys using a pretest-post test design. 
Setting: Kham i M unicipal Clinic, Bulawayo.
Subjects: We interview ed consecutive patients eligible to receive antiretroviral drugs (ARVs). A ll patients 
had a history o f  TB treatm ent and a CD 4 count less than 200 cells/m m .3
M ain O utcome M easures: M ean change in CD4 count, w eight, body m ass index, and K am ofsky 
perform ance m easured before and at six m onths o f  antiretroviral treatm ent.
Results: 72 subjects w ere interview ed at baseline, their m edian age was 38 years (Q, 32 years, Q 3 43 years). 
O f these, 17 (24% ) died before six m onths o f  treatm ent. Three (4% ) defaulted treatm ent follow  up. A total o f  
52 respondents were alive and interview ed at six m onths though only 50, had repeat CD 4 counts at six 
months. Am ong the 50 survivors, the m ean CD 4 count at six m onths w as significantly  h igher than at baseline 
(p=0.0003). There was a 4.2 point statistical significant increase in the m ean w eight from  baseline 
(p=0.0005). Similarly, the m ean Body M ass Index (BM I) significantly increased by 1.5 kg/m ' from  baseline, 
(p=0.001). The m ean K am ofsky  perform ance increased from  89%  at baseline to 95%  at six m onths (p=0004). 
The researchers noted that patients on TB treatm ent w ere being deferred antiretroviral therapy until they 
com pleted TB treatm ent.
Conclusion: The K ham i project bears testim ony that even in a resource poor setting; treatm ent o f  H IV/AID S 
with antiretroviral drugs is feasible. We recom m end early treatm ent initiation for those on TB treatm ent in 
line with national guidelines.
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HIV/AIDS, treatment o f HIV with Highly Active 
Antiretroviral Therapy (HAART) can transform the 
natural course of HIV infection by reducing morbidity 
and mortality as has been observed in many 
industrialized countries.3 It is recommended for 
patients with symptomatic AIDS, WHO Adult Stage IV 
and advanced Stage III irrespective o f the CD4 cell 
count or total lymphocyte count. If  CD4 cell count
In troduction
It was in 1985 that the first case o f HIV tested positive 
in Zimbabwe. The AIDS epidemic has grown since 
then to become one o f the most serious public health 
challenges to ever face the nation.1 According to the 
2003 HIV estimates, 24,6% of adults aged 15 to 49 
years were infected.2 W hilst they cannot cure
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monitoring is unavailable, treatment is recommended 
for symptomatic patients with total lymphocyte counts 
below 1200/mm.4
In Z im b a b w e , la c k  o f  a c c e s s  to 
antiretroviral therapy (ART) was declared an 
emergency in May 2003, paving a way to improve care 
of People Living with HIV and AIDS (PLWA), better 
access to ARVs and authorization to import generics.5 
The ART programme was implemented in public 
health institutions using the phased out approach from 
five learning sites, namely Harare and Mpilo (referral 
Central Hospitals), Howard hospital (rural mission), 
Bulawayo City (local authority) and Triangle Hospital 
(private/public).6 In 2003, it was estimated that 273 000 
had advanced AIDS and needed antiretroviral therapy. 
As o f2004 however, only 8 500 (4.5%) were on ARVs 
countrywide.6
Bulawayo city is the second largest city in 
Zimbabwe with a total population o f 691 728 and a 
growth rate of 1.1%.7 Trends in annual death rates have 
more than doubled since the late 1980s and this has 
been attributed to the HIV pandemic.8 Death rates 
among the economically productive 25 to 44 year age 
group have increased seven to eight fold since 1990. 
Most deaths in this age group were from AIDS and its 
complications.9 In 2002 the death rate in this age group 
was as high as 23 per 1000 population. These high 
death rates are bound to have profound adverse effects 
in the socio-economic development o f communities.9
Bulawayo city introduced antiretroviral (ARV) 
drugs at Khami Clinic in September 2004. The first 
group o f patients was put on ARVs on the 9"' 
September 2004. This project is also being used as one 
of the five learning sites for the national ARV roll out 
programme. The City Health Department provides 
staff, a team of one medical officer, two nurses 
supervised by a Sister-in-Charge o f the clinic and a data 
entry clerk to run the project. Initiation o f the project 
was made possible through financial and technical 
support from John Snow Incorporation (JSI). They 
made a commitment to provide all ARV drug 
requirements for at least 200 patients. The funding also 
covers the costs o f running any laboratory samples, 
which are all done, at Mpilo Central Hospital.
Potential beneficiaries are patients with a history of 
TB treatment and a CD4 count less than 200 cells/mm3. 
Community nurses at local clinics identify potential 
beneficiaries through TB registers and sensitize them. 
They are also encouraged to bring along their wives 
and children for assessment and possible treatment if 
they also have a CD4 count less than 200 cells/mm3. 
Treatment for those with active TB is defeired until 
completion of TB treatment. Initial pre-test and post 
test counseling for HIV is done at the local clinic before 
referral to Khami Clinic. When received at Khami 
Clinic, the patients go through counseling sessions by 
the nurses. These sessions cover among other things, 
issues o f status disclosure; treatment adherence; safer 
sex and risky behavior reduction. Only those willing to 
disclose their status to someone trusted, who in turn
becomes a treatment partner to monitor adherence are 
eligible to receive treatment. Initiation of treatment is 
by the medical officer manning the clinic. The patients 
are put on a cocktail o f Stavudine, Lamivudine and 
Niverapine. Those who develop severe skin reactions 
to Niverapine are switched on to Efavirenz and those 
who develop severe peripheral neuropathy to 
Stavudine are switched on to Zidovudine.
Follow up review o f these patients is scheduled at 2 
weeks of treatment, then monthly thereafter. The 
treatment partner is expected to supervise treatment 
and sign on a 'Daily Observed Treatment Card' after 
each dose is taken.
When the first patient was put on ARVs on the 9,h o f 
September 2004, the local authorities were keen on 
knowing whether these drugs would yield any benefit 
among the intended beneficiaries in the Khami Clinic 
setting. This study offered an opportunity to describe 
treatment outcomes in the first 6 months of treatment.
M ateria ls  and  M ethods
We conducted a pre-intervention post-intervention 
survey using pretest-pos test design. An interview was 
done at enrollment to obtain baseline data on CD4 
count, body weight, body mass index, Kamofsky 
performance and other variables o f interest. This was 
followed by a post-intervention survey to obtain data 
on certain variables and evaluate the effectiveness of 
the intervention at six months after ARVs initiation.
We conveniently sampled consecutive patients who 
were being recruited to receive ARVs between the 9lh 
September 2004 and 28lh January 2005. We included all 
participants enrolled during the limited time available 
to complete fieldwork. Time line projections for the 
project had envisaged that by the end of January 2005, 
at least 100 patients would have been on ARVs. To be 
enrolled into the study one had to be a resident of 
Bulawayo who had never been on ARV treatment, with 
a documented history o f TB treatment in the past 10 
years and a CD4 count less than 200 cells/mm3 at 
baseline.
We used an interviewer-administered questionnaire 
to collect socio-demographic data, casual sex 
partnering and condom use at baseline. An exit 
interview at six months was also done to describe 
household food security during the six months of 
treatment, any changes in casual sex partnering, 
condom use and drug side effects experienced during 
the 6 months treatment. The patients' files were also 
checked at six months for any documented side effects
The Khami project has an inherent mechanism to 
monitor treatment adherence, which was made use of in 
this study. At each visit, patients are given more 
medication than required and instructed to return all 
medication bottles and unused pills at their next visit. 
The returned pills are counted and compared to what 
was given. This is used to compute a percentage rating 
of treatment adherence, as the proportion o f tablets 
swallowed without vomiting o f the expected in a given
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month. This rating is documented in the patient's file at 
each review. For our study, we computed the mean 
adherence rating for each patient over the study period. 
A daily treatment card signed by a treatment partner at 
home after each dose was taken was also checked at six 
months.
Laboratory reports of CD4 counts done before 
treatment were used to compute the mean CD4 count at 
baseline, which was compared to the mean count at six 
months of treatment. This was used to objectively 
assess the immunological response to treatment.
Clinical response to treatment was assessed by 
comparing the mean Kamofsky performance at 
baseline, to that at six months of treatment as well as the 
mean weight of the study subjects at baseline compared 
to that at six months. The weight and height at baseline 
was used to compute the Body Mass Index (BMI), 
which was also compared to computations for 
measurements at six months c f treatment. This variable 
was used as a proxy of changes in nutritional status.
We captured and analyzed data using Epi-info 2002 
statistical package to generate frequencies and tables. 
The paired t-test and Chi-square statistics were used to 
test for statistical significance at 95% confidence level. 
Permission to do the study was obtained from the 
Director, Bulawayo Health Services and the 
Department of community medicine, University of 
Zimbabwe. Verbal consent was obtained from study 
participants.
Study Limitations.
There was potential for recall bias on events that had 
occurred over the six month period. The researchers 
tried to minimize the effects by checking information 
given during interviews against recorded information 
in patients' files and out patients' cards. Only patients 
who had a history of TB treatment were enrolled into 
the study. This presents a special group who have had 
an experience of taking TB drugs for at least six 
months, and may be better motivated and more likely to 
comply to taking ARV medication than the general 
populace.
Study participants were only assessed on 
recruitment when baseline data was collected, and at 
six months following initiation of ARVs. This meant 
that any changes in baseline indicators (CD4 Count; 
patient weight; Kamofsky performance; BMI) during 
the interval between time of subject enrolment and six 
months after treatment could not be determined. Time 
line changes could not be tracked because patients were 
not interviewed between recruitment and at six months.
Certain information like that of side effects for all 
patients recruited relied on accurate and complete 
documentation by the attending medical officer. This 
could have been a source of information bias.
R esults
Demographic data.
There were 72 respondents interviewed at baseline.
Their median age was 3 8 years Q, 32 years, Q3 43 years. 
Table 1 shows demographic characteristics of the study 
population at baseline. Of the 72 respondents enrolled 
at baseline, 17 (24%) died before completing six 
months of treatment and three (4%) defaulted treatment 
follow up. A total of 52 respondents were alive and on 
treatment at six months. These were interviewed at six 
months though only 50 had repeat CD4 counts done at 
six months and only these 50 were used in the treatment 
outcome analysis.
Table I: Frequency distribution o f demographic 
variables o f respondents at baseline, Khami Clinic, 
September 2004 to July 2005.
Variable Frequency
(n=72)
Age (yrs) Median (Q,; Q3) 38 (32;43)
Gender Female*(%) 39 (54)
Male (%) 33 (46)
Marital Status Married (%) 24 (33)




Religion Nil (%) 25 (35)
Protestant (%) 18 (25)
*‘African Apostolic (%) 13(18)
Pentecostal (%) 11(15)
Catholic (%) 5(7)
Education Nil (%) 1(1)
Primary* (%) 17(24)
Secondary (%) 50 (69)
Tertiary (%) 4(6)
(%) Rounded off to the nearest whole number 
** White garmented religious sect
Among those who died, the median duration on 
treatment before dying was observed to be 63 days, 
Q,=32 days; Q3=72 days, implying that aquarter died 
in the first month or (32 days) of treatment and half 
in the first twp months or (63 days) of treatment. A 
comparison of baseline variables of survivors and 
those who died is shown in Table II. It was observed 
that those who died were more likely to score lower 
on the Kamofsky scale than those who survived, at 
baseline, p value: 0.02.
Table II: Comparative distribution o f  baseline 
variables between respondents who survived and those 






Median age (Q,; Q,) 38 (32;43) 37 (33;45) - -
Female gender (%) 
Baseline mean CD4
39(54) 11 (55) -
Count (cells/mm1) 
Baseline mean
79.8 66.1 0.86 0.12
weight (kg) 
Kamofsky
54.5 50.8 1.14 0.09
performance (%) 88.6 75.9 6.08 0.02
‘ Independent t-test used **95% level of significance used
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Treatment Outcomes.
(I) Immunological response.
Among survivors, the mean CD4 count was 80 
cells/mm3 at baseline, compared to 200 cells/mm3 at six 
months. The increase from baseline was found to be 
statistically significant, p value: 0.0003. The median 
increase in CD4 count from baseline was 110 
.cells/mm3, Q,=68; Q3=170. The majority, 15 (30%), 
had an increase in CD4 count from baseline in the 
range, 101 to 150 cells/mm3. Only three (6%) had CD4 
counts decreasing from baseline. As the magnitude of 
increase in CD4 count from baseline got larger, so did 
the increase in mean weight from baseline. There was 
an inverse relation observed in the magnitude of 
increase in CD4 count and the CD4 count at baseline, 
implying that those who had very large increases in 
CD4 count were likely to have had very low CD4 
counts at baseline. Table III shows magnitude of 
changes in CD4 coynt from baseline among survivors.
Table III: Changes in CD4 count from baseline to six 
months after ARV initiation in relation to other 










*< 0 3(6) 1.7 153.3 86.7
0-50 3(6) 6.3 80.7 90.0
51-100 14(28) • 2.9 63.8 89.2
101-150 15(30) 4.3 95.1 90.7
151-200 9(18) 4.9 65.4 85.6
>200 6(12) 4.7 66.3 83.3
*CD4 decreased from baseline
(II) Clinical response.
The mean weight increased from 54.5 kg to 58.7 kg and 
this increase was statistically significant, p value:
0.0005. Similarly, the mean (BMI) significantly 
increased from 20.4 kg/m2 to 21.9 kg/m2, p-value: 
0.001. The mean Kamofsky performance increased 
from 88.6% to 95.2% and this increase was statistically 
significant, p-value: 0.0004. Table IV shows treatment 
outcomes of survivors who had a repeat CD4 at six 
months.
Table IV: Changes in CD4 count from baseline after 
ARV initiation in relation to other variables among 
survivors on AR Vs at Khami clinic.





CD4 count (/mm1) 79.8 199.9 -10.4 0.0003
Weight (kg) 54.5 58.7 -6.5 0.0005
BMI (kg/m2 20.4 21.9 -6.2 0.001
Kamofsky 
performance (%) 88.6 95.2 -7.9 0.0004
‘ Paired t-test used **95% level of significance used
The occupational status among survivors improved 
after 6 months of treatment. At baseline, only 21 (40%) 
were gainfully employed and as many as 22 (43%) had 
retired from work on medical grounds. At six months, 
the proportion of those gainfully employed increased to 
34 (66%). Half (11/22) of those who had retired from 
work on medical grounds had gone back to work at six 
months. Figure 1 shows changes in occupational status 
from baseline.
Figure I: Changes in occupational status among survivors from baseline.
O ccupational status among survivors on 
ARVs at baseline, Khami clinic, Sep.04- 
Jul.05 (n:52)
Retired on 
medical 43%  
grounds
Treatment Adherence and Follow Up.
Among survivors, seven (16%) reported that they 
missed at least a dose o f their medication in the six 
months. The most frequently mentioned reason was 
forgetfulness. Overall, each subject took their
medication between 95 % and 100% of the time. 
Nineteen (37%) reported that at times more than 30 
minutes may elapse before taking medication and 23 
(44%) reported they had no one reminding them to take 
their medication. Only two (4%) felt that the quantity of
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tablets taken per day was too much.
Only four (8%) reported ever missing a review date 
in the six months, either because they had forgotten the 
review date or had to attend some social event. Twenty 
(39%) found coming for review was too expensive, 
similarly 20 (39%) preferred to be reviewed at their 
local clinic to minimize transport expenses.
Experienced Side Effects to ARVs.
The frequency of side effects among all 72 subjects was
Figure II: Frequency distribution o f  side effects.
23 (32%). Peripheral neuropathy was the most 
frequently documented side effect. Four (6%) had to 
switch on to a different drug combination because of 
severity of side effects. Figure II shows the frequency 
distribution of side effects experienced by the study 
subjects.












Among the survivors, the median size of household 
was four; Q,=3; Q3=6. Twelve (23%) reported they had 
less than three (two or one) as the average number of 
meals taken per day and 19 (37%) reported that they at 
times missed meals because they had nothing to cook 
during the six months of treatment. Fifteen (29%) 
reported they had no vegetable garden and 45 (87%) no 
fowl run at home.
Public Health Issues.
The proportion reporting having had sex in the last 
three months was 35% at baseline. This proportion 
significantly increased to 40% at six months, p value 
0.0001. We, however, did not observe any significant 
increase in consistent condom use at six months from 
baseline, p value 0.60.
Among survivors, the proportion that reported 
having slept with a casual partner in the last three 
months at base line was five (10%), which was not 
different from the proportion reporting at six months, 
five (10%).
Only two out of 24 male respondents interviewed at 
six months could not correctly describe how to use a 
male condom and as high as 13 out of 28 female 
respondents could not correctly describe how to use a 
female condom. When asked at six months how many 
times a single male condom can be used, six (12%) of 
all respondents had no clue and as high as 29 (56%) had 
no idea how many times a single female condom can be
used.
At six months, 20 (38%) had a regular sex partner. Of 
these three (15%) had not disclosed their status to their 
partner. Among those who had disclosed status to their 
regular partner, reasons for disclosure were to protect 
their partner by engaging in protected sex and to help 
their partner to enroll into the ARV programme. Among 
those with a regular partner at six months, 16 (80%) 
had their partner enrolled into the ARV programme at 
the time of the exit interview.
Five (10%) reported they at times shared their drugs 
with someone, usually a spouse also on ARVs and five 
(10%) reported they at times took alcohol during the six 
months under review.
D iscussion
Bulawayo City introduced an ARV programme at one 
of its municipal clinics in September 2004. Potential 
beneficiaries were previously treated TB patients, their 
spouses and children. The focus of this study was to 
describe treatment outcomes of these patients after six 
months of treatment.
Treatment Outcomes.
Among the 52 subjects who were alive at six months, 
results of this study indicate favorable outcomes for 
most variables measured at six months compared to 
measurements at baseline. The mean change in CD4
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count was an increase of 120 cell/mm3. This is 
consistent with expected changes in patients with 
optimal ARV therapy. The CD4 count is expected to 
increase by more than 100 cells/mm3 in the first 6 to 12 
months on ARVs.10 Similarly, the mean weight and 
mean body mass index significantly increased by 4.2 
kg and 1.5 kg/m2 respectively. Findings, however, fall 
short of outcomes observed in a similar project in 
Khayelitsha, South Africa, where outcomes there were 
more favorable: The mean CD4 cell count change from 
baseline was observed to be 133 cells/mm3 and the 
mean weight gain, 6.1kg at six months. Only 12 % died 
in the first six months of treatment unlike in our study 
where mortality was twice as high.'1
Treatment Adherence.
Favourable treatment outcomes observed in this study 
were coupled with very high rates of treatment 
adherence, of above 95%. These findings are consistent 
with findings by Orel, et al. in Cape Town, who found 
rates of adherence as high as 93.5%." Very high levels 
of adherence to lifelong Highly Active Anti- retroviral 
Treatment (HAART) are a pre-requisite for a 
successful virological and immunological response.13 
Levels of adherence below 95% have been associated 
with poor virological and immunological response. For 
the individual, low levels of adherence are associated 
with the development of viral resistance, treatment 
failure and disease progression. From a public health 
perspective, the emergence of resistant strains of HIV 
due to poor ARV adherence is likely to result in an 
increase in the transmission of resistant virus to newly 
infected individuals13.
The concept of a treatment partner who supervises 
treatment at home was observed as a critical 
programmatic component of the Khami project. This is 
consistent with observations in similar projects 
elsewhere. The Botswana ARV programme is 
successfully employing a “buddy system” where each 
patient is encouraged to form a special bond with 
someone who makes sure they take their medication.14 
In the Khayelitsha project, adherence support involves 
a treatment assistant, usually someone living in the 
patient's household, who can assist with adherence 
issues." We, however, observed in our study, that 
though all patients had brought a treatment partner as a 
pre requisite for initiation of treatment at baseline, as 
high as 44% reported they had no one reminding them 
to take their medication at six months.
Drug side effects.
The incidence of side effects severe enough to require 
change in treatment was uniformly low. Only 6% had to 
switch on to a different drug combination because of 
severity o f side effects. This is consistent with 
observations in the Khayelitsha project, where 8% of 
patients needed to change an individual drug due to 
adverse events."
Tuberculosis is the commonest opportunistic 
infection encountered among persons with HIV in
Zimbabwe.6 Studies have shown that up to 50% of 
persons with HIV infection develop TB and that up to 
85% of persons with TB have HIV infection.15 The 
treatment of HIV in those co-infected with HIV and TB 
has conventionally been deferred because of concerns 
for drug interactions with rifampicin in particular, 
which may potentially increase the incidence of drug 
reactions and toxicity.15 These fears are reiterated in the 
Khami clinic project, where those with active TB 
treatment are deferred until they complete TB 
treatment. The implications are that, these very ill 
patients, invariably in WHO stage three and four of 
AIDS are conveniently delayed in being initiated on 
these potentially life saving drugs. However, current 
and recently revised CDC guidelines indicate that 
rifampicin can be given concurrently with certain non­
nucleoside reverse transcriptase inhibitors, like 
efavirenz, in patients being treated for TB.15 Guidelines 
for antiretroviral therapy in Zimbabwe recommend 
that ARVs be commenced in those patients with extra- 
pulmonary TB or any TB patient with a CD4 count less 
than 200 cells/mm3.16
Household Food Security.
More than a third of respondents reported that they at 
times missed meals because they had nothing to cook 
during the six months of treatment. These observations 
raise pertinent questions on household food security. It 
is clear, a substantial proportion face food scarcity at 
household level, which has a negative impact on 
treatment outcomes. The relationship between HIV and 
malnutrition presents a classic example of the “vicious 
cycle” of immune dysfunction, infectious disease and 
malnutrition. Any immune impairment that results 
from HIV infection leads to immune impairment, 
worsens the effect of HIV and contributes to more rapid 
progression to AIDS.17 An HIV infected person requires 
an additional energy intake of 10 to 15%.17
Public Health Concerns.
Among 20 patients who had a regular sex partner at six 
months, three (15%) had not disclosed their status to 
their sexual partner. Among those who had disclosed, 
some of the reasons for status disclosure were to protect 
their partner by engaging in protected sex and to help 
their partner to enroll into the ARV program. This is 
consistent with observations by Simoni et al. who 
found that ethical responsibility and concern for 
partner's health was the major reason cited for 
disclosing to sexual partners.18
Within HIV testing and counseling programmes, 
emphasis is placed on the importance of status 
disclosure among HIV infected clients, particularly to 
their sexual partners.19 Disclosure is an important 
public health goal for a number o f different reasons. 
Disclosure may motivate sexual partners to seek 
testing, change behavior and ultimately decrease 
transmission of HIV.19
Exposure to the Khami project did not change the 
proportion who reported having slept with a casual
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partner in the last three months at six months, compared 
to observations at baseline. Neither was there any 
significant increase in consistent condom use from 
baseline, p value 0.60. These findings are a sharp 
contrast to observations in Khayelitsha, where the ARV 
project resulted in a significant increase in uptake of 
HIV prevention interventions such as HIV testing and 
counseling, and condom use." As many as 13 (46%) of 
28 female respondents could not correctly describe 
how to use a female condom and more than 50% of all 
respondents had no idea how many times a single 
female condom can be used. This knowledge gap 
represents the magnitude of neglect in empowering the 
female gender in having some degree of control over 
the sexual act and promoting use of a female condom.
Among those interviewed at six months, 10% 
reported they at times shared their drugs with someone, 
usually a spouse also on ARVs. This disturbing 
phenomenon, if left unchecked, has the potential to 
compromise optimal treatment adherence. Muula et 
al. in Malawi also observed pill sharing with a spouse 
prevalent among patients on ARVs.20
Conclusion.
The Khami ARV project in Bulawayo bears testimony 
that even in a resource poor Primary Health care 
setting, treatment of HIV/AIDS with ARV drugs is 
feasible. This has been evidenced by favorable clinical 
outcomes among survivors despite challenges in 
household food security.
Of public health concern is that there were no 
significant changes in casual sex partnering and 
consistent condom use after six months of exposure to 
the programme.
It is regrettable that the programme offers only a first 
line treatment regimen with no salvage regimen in case 
of treatment failure and there is no laboratory capacity 
to detect drug resistance. However, it should be noted 
that there are only a few public health facilities in the 
country that offer second line salvage regimens.
Recom m endations.
There is need to initiate ART to eligible TB patients 
according to national guidelines so as to improve 
prognosis. The authors recommend that the city health 
directorate engage social welfare and donor partners to 
economically empower patients on ARVs through 
income generating projects so as to ensure household 
food security, to maximize treatment outcomes.
Khami Clinic staff need to reinforce counseling on 
reduction of risky behavior, with emphasis on casual 
sex partnering and consistent condom use. Equipping 
female patients on how to use a female condom could 
go a long way in empowering them to have some 
measure of control over their sex life. There is urgent 
need to decentralize patient reviews to alleviate 
transport costs on patients.
The authors also recommend a study to assess to
what extent quality of care relates to treatment
outcomes and mortality at the Khami Clinic setting.
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